Efficacy and safety of bi‐weekly cofrogliptin treatment replacing daily dipeptidyl peptidase‐4 inhibitors in Chinese patients with type 2 diabetes mellitus: A multicenter, open‐label, randomized controlled phase 2 trial
Bi-weekly cofrogliptin treatment, instead of daily DPP-4i, could effectively control blood glucose levels in a 24-week treatment period and their fluctuations and was well tolerated in Chinese patients with T2DM.
Authors
- Yanli Zhou (ORCID: https://orcid.org/0000-0002-4008-4590)
- Suijun Wang
- Zhongjing Wang (ORCID: https://orcid.org/0000-0001-9374-564X)
- Fangqiong Li (ORCID: https://orcid.org/0009-0005-2092-5099)
- Jin Zhang (ORCID: https://orcid.org/0000-0001-7009-8865)
- Liming Chen (ORCID: https://orcid.org/0000-0002-5682-2340)
- Yaming Li
- Yi Feng
- Zhanhui Zhang (ORCID: https://orcid.org/0000-0003-4038-9279)
- Hongwei Jiang (ORCID: https://orcid.org/0009-0000-2174-4904)
- Congqing Pan (ORCID: https://orcid.org/0000-0002-9766-9629)
Institutions
- University of Shanghai for Science and Technology (CN)
- Leshan Normal University (CN)
- China National Pharmaceutical Group Corporation (China) (CN)
- Zhongshan People's Hospital (CN)
- Bozhou People's Hospital (CN)
- Pudong Medical Center (CN)
- First Affiliated Hospital of Henan University of Science and Technology (CN)
- Central Hospital of Wuhan (CN)
- Tianjin Medical University (CN)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-11-20
- DOI
- https://doi.org/10.1111/dom.70305
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00